Stockscreener 앱 받기
2.345
2.70%
-0.065
시간 외 거래:
2.32
-0.025
-1.07%
전일 마감가:
$2.41
열려 있는:
$2.91
하루 거래량:
71.94M
Relative Volume:
19.72
시가총액:
$199.72M
수익:
-
순이익/손실:
$-59.69M
주가수익비율:
-1.6871
EPS:
-1.39
순현금흐름:
$-46.54M
1주 성능:
-11.84%
1개월 성능:
+17.25%
6개월 성능:
+42.12%
1년 성능:
+30.28%
1일 변동 폭
$2.10
$2.92
1주일 범위
$1.61
$3.06
52주 변동 폭
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
MIST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.345 | 205.26M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com UK
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
Milestone’s long regulatory road ends in approval for Cardamyst - PharmaLive
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST - TipRanks
Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday?Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone Pharmaceuticals (MIST) Stock: Wild Price Swings Follow FDA Approval Decision - Blockonomi
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns - Stocktwits
Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition - TradingView — Track All Markets
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Strengthens Cardiovascular Research - Kalkine Media
Milestone Pharmaceuticals (MIST) Receives FDA Approval for CARDA - GuruFocus
Milestone Pharmaceuticals Sees Stock Recovery Despite Market Volatility - StocksToTrade
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025) - ts2.tech
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Wall Street Zen to Sell - MarketBeat
Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray - Stock Titan
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewswire Inc.
Rocket Lab (RKLB) Stock News Today: Neutron “Hungry Hippo” Milestone, Launch Updates, and Analyst Forecasts (Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025) - ts2.tech
Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results - timothysykes.com
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - setenews.com
Is Milestone Pharmaceuticals Inc. stock recession proofDip Buying & Long-Term Growth Stock Strategies - Newser
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals (Nasdaq: MIST) issues 30,000 options at $2.69 under 2021 Inducement Plan - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
EV Market: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Momentum & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
Milestone Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:MIST) - Defense World
Milestone Pharmaceuticals Inc (MIST) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Will Milestone Pharmaceuticals Inc. stock gain from lower inflation2025 Volatility Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Healthy Upside Potential: Milestone Pharmaceuticals Inc (MIST) - setenews.com
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Insider Monkey
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Grasim Industries Limited Trading Near Value Zone Recovery AheadRetail Investor Activity & Low Entry Risk Stocks - earlytimes.in
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Business Wire
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth - MSN
Milestone Pharmaceuticals Inc. (MIST) stock price, news, quote and history - Yahoo Finance UK
Milestone Pharmaceuticals Inc. (MIST) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is Milestone Pharmaceuticals Inc. stock bottoming outJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
How analysts rate Milestone Pharmaceuticals Inc. stock today2025 Market Trends & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-20 02:01:48 - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 17:33:54 - newser.com
Why analysts remain bullish on Milestone Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-11-19 13:39:11 - newser.com
It makes sense and dollars to buy Milestone Pharmaceuticals Inc (MIST) stock - Setenews
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):